Determination of EFONIDIPINE (cas 111011-63-3) in human plasma by LC–MS/MS for pharmacokinetic applications

Add time:08/23/2019    Source:sciencedirect.com

EFONIDIPINE (cas 111011-63-3) hydrochloride is a new generation dihydropyridine calcium channel blocker designed to inhibit both T-type and L-type calcium channels. For the first time, a simple and robust LC–MS/MS method was developed for the determination of efonidipine in human plasma over the range of 0.100–20.0 ng/mL. Efonidipine was extracted from plasma by an LLE procedure, separated by LC and detected by MS/MS in positive mode ESI. The method was validated for selectivity, carryover, sensitivity, extraction recovery, matrix effects, linearity, accuracy and precision, dilution integrity and stability studies. The calibration curves were linear over 0.100–20.0 ng/mL (r ≥ 0.9980). The lower limit of quantification (LLOQ) was established at 0.100 ng/mL. Intra- and inter-day precisions (LLOQ, low-QC, mid-QC, high-QC and ultra-high QC) were less than 12.5% in terms of relative standard deviation (RSD), and accuracies were between −5.0% and 5.0% in terms of relative error (RE). Matrix effect was acceptable (105.6–110.2%) and extraction recovery was reproducible (85.8–91.3%, RSD ≤ 10.0%). Efonidipine was stable in the investigated conditions. The method was applied to the pharmacokinetics of efonidipine in human subject.

We also recommend Trading Suppliers and Manufacturers of EFONIDIPINE (cas 111011-63-3). Pls Click Website Link as below: cas 111011-63-3 suppliers

Prev:Research paperIncreased bioavailability of EFONIDIPINE (cas 111011-63-3) hydrochloride nanosuspensions by the wet-milling method
Next:A chiral LC–MS/MS method for the stereospecific determination of EFONIDIPINE (cas 111011-63-3) in human plasma)